BIOCONJUGATES
Accelerate Your ADC Program
Altruist Biologics provides end-to-end development and manufacturing for antibody drug conjugates (ADCs) and other novel bioconjugates. Through our integrated capabilities for ADC clinical to commercial manufacturing, we can accelerate your timelines, de-risk and reduce complexities, and meet all product quality requirements.
Our Integrated Capabilities
Our comprehensive services span every critical component of your ADC program – from linker-payload intermediates and antibodies through to the final bioconjugate drug substance and drug product.
Explore Our Capabilities:
Our Platforms
- ADC – Antibody Drug Conjugate
- APC – Antibody Peptide Conjugate
- ACC – Antibody Chelator Conjugate
- DAC – Degrader Antibody Conjugate
- PEG – PEGylation-Based Conjugate
- ISAC – Immuno-Stimulant Antibody Conjugate
- AOC – Antibody Oligonucleotide Conjugate
- Dual Payload – Dual Payload Antibody Conjugate
- BsADC – Bispecific Antibody Drug Conjugate
Parallel Development of mAb and ADC
Our Value Chain From DNA to ADC
Bridging the gap between drug discovery and commercial supply, we offer tailored CMC development for bioconjugation and antibody drug conjugates.
Our Track Record
35+ ADC & AXC Projects
15+
Pre-IND ADC & AXC
8+
IND Enabling
(FDA, NMPA)
10+
Phase I & II
(2 FTD)
2
Phase III & PPQ
(FDA, EMA, PMDA, NMPA)
DEDICATED GMP FACILITIES
State-of-the-Art Equipment and Flexible Design
We provide synergy with existing systems and procedures for both mAbs and ADCs to accelerate timelines.
Hangzhou Site
Our dedicated ADC facility in Hangzhou features single-use reactor systems supporting conjugation scales of up to 500 L (1000L-5,000L are under construction), providing the flexibility and capacity required for scalable ADC manufacturing. The site includes fully integrated laboratories dedicated to ADC process development, quality control (QC), and MSAT to support seamless progression from development through manufacturing.
The facility is designed for the safe handling of high-potency APIs (HPAPIs) and incorporates stringent high-containment systems with an Occupational Exposure Limit (OEL) capability of 5 ng/m³, ensuring the highest standards of safety, regulatory compliance, and operational control.
Manufacturing Capacities Across the Entire Value Chain
| Suzhou AXC Pilot Plant | -Bioconjugation Drug Substance: 1g–1,500g/batch -Dedicated AXC Pilot Plant -Scale Up Experience: 100g, 150g, 500g, 5,000g |
| Hangzhou AXC Commercial Facility | -ADC Drug Substance Plant: 20L–100L -Commercial Drug Substance: 100L–500L, 500L–5,000L* -Commercial Drug Product: 2 x 7.5m² lyophilizer, 2 x 35m² lyophilizer* (*Under construction) |
Contact
Let’s Move Medicine Forward
Leverage our end-to-end ADC expertise to quickly bring your life-changing drug to patients in need.